SPEC.ST Stock Analysis
SP
Uncovered
SpectraCure AB (publ) is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
SpectraCure AB engages in the research, development, and provision of equipment for cancer treatments. The company is headquartered in Lund, Skane. The company went IPO on 2015-07-01. The firm specializes in cancer treatment technology. The firm develops photodynamic therapeutics based on photosensitive materials activated by laser. The firm's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.